The new drug registration cycle at Malaysia’s NPRA lags behind that of some other countries; publicly available information indicates the gap is usually 2-4 years. This leads some patients who have run out of standard options locally to look into innovative drugs already approved in China. This article explains how to search for and verify drug availability; it does not recommend any specific medication.
1. How the time gap arises
For a new drug to be used legally in Malaysia, it must complete registration review. The pace of review is affected by multiple factors, including when the application is filed, how complete the dossier is and local clinical need. The same drug therefore does not become available at the same time in every country.
For patient families, this gap creates a practical problem: the local doctor judges by the locally approved list and concludes that there is no standard option left, but that list does not include products already marketed in other countries.
2. How to verify whether a drug is approved in China
Cross-check in the following order rather than relying on a single source:
- Generic name: first confirm the drug’s international non-proprietary name (INN) to avoid confusion with brand names.
- NMPA public database: check the approval status, the wording of the indication and the marketing authorisation holder.
- Brand names and dosage forms: the same generic name may be sold under different brand names and strengths, which need to be matched one by one.
- Approved indication: confirm whether the stated indication covers the patient’s specific subtype and line of treatment.
- Medical insurance and self-pay status: whether the drug is on the reimbursement list directly determines the share the patient pays.
One important reminder: “approved” does not mean “suitable for you”. The wording of the indication, previous treatment history, genetic subtype and performance status all affect whether a doctor will use it.
3. The compliant pathway for receiving treatment in China
| Step | Content | Completed by |
|---|---|---|
| Record preparation | A bilingual file of pathology, genetic testing and previous treatment records | Platform assistance |
| Pathology re-review | In-hospital re-review of slides and additional staining where necessary | Hospital pathology department |
| Outpatient visit or written consultation | The relevant department judges whether the conditions for treatment are met | Treating physician |
| Prescription and administration | Issuing prescriptions, in-hospital administration and monitoring | Hospital |
| Medication on discharge | English summary of doctor’s orders and prescription instructions | Hospital |
4. Limits on carrying medication across borders
Carrying prescription drugs across borders involves the regulations of both countries. The general principles are: carry a valid prescription and medical certificate, carry a reasonable quantity for personal use, and declare it proactively. Different drugs have different control levels, so each one should be confirmed before travelling; do not assume that anything a doctor prescribes can be carried.
5. Frequently asked questions
Q: If my local doctor says there are no drugs left, is it worth checking another country’s list? Yes, but the purpose is to bring it back to your local doctor for discussion, or to inform a decision on whether further consultation is needed, not to buy medication yourself.
Q: Can we have a written consultation first and then decide whether to travel to China? Yes. Most families obtain a written opinion first and then plan their trip.
Q: Will the platform recommend a specific drug? No. The platform helps organise records, arrange consultations and translate documents. Decisions on medication are made by licensed physicians.
Any decision on medication must be made by a licensed physician based on the patient’s actual condition. This article does not constitute medication advice or a promise of efficacy.